New Investor Group Acquires 19.99% Stake and Board Seats in Cingulate Inc. via $11M Private Placement
CING has more than doubled off its 52-week low of $3.2 on elevated volume (2.3× avg).
Summary
Falcon Creek Capital Advisor and its affiliates have acquired a 19.99% beneficial ownership in Cingulate Inc. through an $11 million private placement, gaining significant board representation and providing crucial capital to the company.
Key Events · Ownership and Investor Activity · CING
-
Significant New Investor Group
Falcon Creek Capital Advisor LLC, Falcon Creek Technology Fund I, LP, and Ginkgo Capital Global Fund SPC - Xtalpi AI Fund SP have collectively reported beneficial ownership of 19.99% of Cingulate Inc.'s outstanding common stock.
-
Substantial Capital Infusion
The investor group acquired securities through a private placement totaling approximately $11.0 million, providing a significant capital boost to the company.
-
Board Representation and Influence
The new investors are entitled to designate one director immediately and a second director upon stockholder approval, along with a non-voting board observer until the second director is appointed, indicating substantial governance influence.
-
Private Placement Details
The acquisition involved 1,951,946 shares of common stock, 973 shares of Series A convertible preferred stock (convertible at $5.04/share), and warrants to purchase 1,868,482 shares of common stock (exercise price $5.04/share), priced at a discount to the current market price.
Analysis · CING · Life Sciences
This Schedule 13D filing reveals that Falcon Creek Capital Advisor LLC and its affiliated funds have acquired a significant 19.99% beneficial ownership stake in Cingulate Inc. through a private placement totaling over $11 million. This transaction, which includes common stock, convertible preferred stock, and warrants, is a critical financing event for Cingulate, following a series of capital-raising activities in recent weeks. The new investor group will gain substantial influence with the right to designate up to two directors to the Board and a non-voting observer, pending stockholder approval for the second director. While the offering is dilutive, securing this level of capital and a strategic investor with board representation is a vital step for the company's operational runway and future strategic direction, especially given its active pursuit of funding.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $7.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.5M. The 52-week trading range was $3.20 to $7.92. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.